Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G, Ecker J, Selt F, Hielscher T, Sigaud R, Ridinger J, Thatikonda V, Gatzweiler C, Robinson S, Talbot J, Bernardi F, Picard D, Blattner-Johnson M, Schmid S, Jones DT, van Tilburg CM, Capper D, Kool M, Remke M, Oehme I, Pfister SM, Roussel MF, Ayrault O, Witt O, Milde T. Valinciute G, et al. Among authors: picard d. J Neurooncol. 2023 May;163(1):143-158. doi: 10.1007/s11060-023-04319-1. Epub 2023 May 15. J Neurooncol. 2023. PMID: 37183219 Free PMC article.
CD155 is a putative therapeutic target in medulloblastoma.
Li S, McLendon R, Sankey E, Kornahrens R, Lyne AM, Cavalli FMG, McKay Z, Herndon JE 2nd, Remke M, Picard D, Gromeier M, Brown M, Thompson EM. Li S, et al. Among authors: picard d. Clin Transl Oncol. 2023 Mar;25(3):696-705. doi: 10.1007/s12094-022-02975-9. Epub 2022 Oct 27. Clin Transl Oncol. 2023. PMID: 36301489
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Marquardt V, et al. Among authors: picard d. J Immunother Cancer. 2023 Jan;11(1):e005871. doi: 10.1136/jitc-2022-005871. J Immunother Cancer. 2023. PMID: 36639156 Free PMC article.
UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.
Paisana E, Cascão R, Custódia C, Qin N, Picard D, Pauck D, Carvalho T, Ruivo P, Barreto C, Doutel D, Cabeçadas J, Roque R, Pimentel J, Miguéns J, Remke M, Barata JT, Faria CC. Paisana E, et al. Among authors: picard d. Neurooncol Adv. 2023 Apr 28;5(1):vdad048. doi: 10.1093/noajnl/vdad048. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37215954 Free PMC article.
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma.
Picard D, Felsberg J, Langini M, Stachura P, Qin N, Macas J, Reiss Y, Bartl J, Selt F, Sigaud R, Meyer FD, Stefanski A, Stühler K, Roque L, Roque R, Pandyra AA, Brozou T, Knobbe-Thomsen C, Plate KH, Roesch A, Milde T, Reifenberger G, Leprivier G, Faria CC, Remke M. Picard D, et al. Acta Neuropathol. 2023 Oct;146(4):551-564. doi: 10.1007/s00401-023-02626-5. Epub 2023 Sep 1. Acta Neuropathol. 2023. PMID: 37656187 Free PMC article.
The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
Qin N, Paisana E, Picard D, Leprivier G, Langini M, Custódia C, Cascão R, Conrad C, Peitzsch M, Stefanski A, Stühler K, Fischer U, Faria CC, Dietrich S, Reifenberger G, Remke M. Qin N, et al. Among authors: picard d. J Neurooncol. 2023 Nov;165(2):329-342. doi: 10.1007/s11060-023-04508-y. Epub 2023 Nov 17. J Neurooncol. 2023. PMID: 37976029 Free PMC article.
Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia.
Blumel L, Bernardi F, Picard D, Diaz JT, Jepsen VH, Hasselmann R, Schliehe-Diecks J, Bartl J, Qin N, Bornhauser B, Bhatia S, Marovka B, Marsaud V, Dingli F, Loew D, Stanulla M, Bourqin JP, Borkhardt A, Remke M, Ayrault O, Fischer U. Blumel L, et al. Among authors: picard d. Haematologica. 2024 Jul 1;109(7):2290-2296. doi: 10.3324/haematol.2023.283928. Haematologica. 2024. PMID: 38426288 Free PMC article. No abstract available.
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
Kocher D, Cao L, Guiho R, Langhammer M, Lai YL, Becker P, Hamdi H, Friedel D, Selt F, Vonhören D, Zaman J, Valinciute G, Herter S, Picard D, Rettenmeier J, Maass KK, Pajtler KW, Remke M, von Deimling A, Pusch S, Pfister SM, Oehme I, Jones DTW, Halbach S, Brummer T, Martinez-Barbera JP, Witt O, Milde T, Sigaud R. Kocher D, et al. Among authors: picard d. J Neurooncol. 2024 Jun;168(2):317-332. doi: 10.1007/s11060-024-04672-9. Epub 2024 Apr 17. J Neurooncol. 2024. PMID: 38630384 Free PMC article.
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases.
Jeising S, Nickel AC, Trübel J, Felsberg J, Picard D, Leprivier G, Wolter M, Huynh MK, Olivera MB, Kaulich K, Häberle L, Esposito I, Klau GW, Steinmann J, Beez T, Rapp M, Sabel M, Dietrich S, Remke M, Cornelius JF, Reifenberger G, Qin N. Jeising S, et al. Among authors: picard d. J Neurooncol. 2024 Sep;169(3):613-623. doi: 10.1007/s11060-024-04763-7. Epub 2024 Jul 10. J Neurooncol. 2024. PMID: 38985431 Free PMC article.
489 results